This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saylors, R. L. Articles by Vietti, T. J. Search for Related Content PubMed PubMed Citation Articles by Saylors, R. L., III Articles by Vietti, T. J. Social Bookmarking                            What's this?

Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study

From the University of Arkansas for Medical Sciences, Little Rock, AR; the Pediatric Oncology Group Statistical Office, Gainesville, FL; Cardinal Glennon Children’s Hospital, and Washington University School of Medicine, St Louis, MO; Hackensack University Medical Center, Hackensack, NJ; and University of Montreal, Montreal, Canada.

Address reprint requests to Robert L. Saylors III, MD, Children’s Oncology Group Offices, 440 E Huntington Dr, PO Box 60012, Arcadia, CA 91006-6012.

PURPOSE: To determine the response rate of the combination of cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors.

PATIENTS AND METHODS: A total of 91 pediatric patients, 83 of whom were fully assessable for response and toxicity, received cyclophosphamide (250 mg/m²/dose) followed by topotecan (0.75 mg/m²/dose), each given as a 30-minute infusion daily for 5 days. All patients received filgrastim (5 mcg/kg) daily until the absolute neutrophil count (ANC) was 1,500 µL after the time of the expected ANC nadir.

RESULTS: A total of 307 treatment courses were given to the 83 fully assessable patients. Responses (complete response plus partial response) were seen in rhabdomyosarcoma (10 of 15 patients), Ewing’s sarcoma (six of 17 patients), and neuroblastoma (six of 13 patients). Partial responses were seen in two of 18 patients with osteosarcoma and in one patient with a Sertoli-Leydig cell tumor. Twenty-three patients had either minor responses (n = 6) or stable disease (n = 17); the median number of courses administered to patients with partial or complete response was six (range, two to 13 courses), and the median administered to those with stable disease was three (range, one to 11 courses). The toxicity of the combination was limited principally to the hematopoietic system. Of 307 courses, 163 (53%) were associated with grade 3 or 4 neutropenia, 84 (27%) with grade 3 or 4 anemia, and 136 (44%) with grade 3 or 4 thrombocytopenia. Despite the severe myelosuppression, only 34 (11%) of 307 courses were associated with grade 3 or 4 infection. Nonhematopoietic toxicity of grades 3 was rare and consisted of nausea and vomiting (two courses), perirectal mucositis (one course), transaminase elevation (one course), and hematuria (two courses).

CONCLUSION: The combination of cyclophosphamide and topotecan is active in rhabdomyosarcoma, neuroblastoma, and Ewing’s sarcoma. Stabilization of disease was seen in osteosarcoma, although objective responses were rare in this disease. The therapy can be given with acceptable hematopoietic toxicity with the use of filgrastim support.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. A.S. Arndt, J. A. Stoner, D. S. Hawkins, D. A. Rodeberg, A. A. Hayes-Jordan, C. N. Paidas, D. M. Parham, L. A. Teot, M. D. Wharam, J. C. Breneman, et al. Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 J. Clin. Oncol., November 1, 2009; 27(31): 5182 - 5188. [Abstract] [Full Text] [PDF]

				M. K. Lessig The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment Journal of Pediatric Oncology Nursing, July 1, 2009; 26(4): 208 - 216. [Abstract] [PDF]

				R. A. Daniel, A. L. Rozanska, H. D. Thomas, E. A. Mulligan, Y. Drew, D. J. Castelbuono, Z. Hostomsky, E. R. Plummer, A. V. Boddy, D. A. Tweddle, et al. Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma Clin. Cancer Res., February 15, 2009; 15(4): 1241 - 1249. [Abstract] [Full Text] [PDF]

				C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858. [Abstract] [Full Text] [PDF]

				P. Schaiquevich, J. C. Panetta, L. C. Iacono, B. B. Freeman III, V. M. Santana, A. Gajjar, and C. F. Stewart Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients Clin. Cancer Res., November 15, 2007; 13(22): 6703 - 6711. [Abstract] [Full Text] [PDF]

				H. Peng, Y. Sohara, R. A. Moats, M. D. Nelson Jr., S. G. Groshen, W. Ye, C. P. Reynolds, and Y. A. DeClerck The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation Cancer Res., October 1, 2007; 67(19): 9346 - 9355. [Abstract] [Full Text] [PDF]

				B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma J. Clin. Oncol., November 20, 2006; 24(33): 5271 - 5276. [Abstract] [Full Text] [PDF]

				M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]

				T. Schluep, J. Hwang, J. Cheng, J. D. Heidel, D. W. Bartlett, B. Hollister, and M. E. Davis Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models Clin. Cancer Res., March 1, 2006; 12(5): 1606 - 1614. [Abstract] [Full Text] [PDF]

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]

				L. M. Barker, T. W. Pendergrass, J. E. Sanders, and D. S. Hawkins Survival After Recurrence of Ewing's Sarcoma Family of Tumors J. Clin. Oncol., July 1, 2005; 23(19): 4354 - 4362. [Abstract] [Full Text] [PDF]

				N. Marina and P. A. Meyers High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission J. Clin. Oncol., July 1, 2005; 23(19): 4262 - 4264. [Full Text] [PDF]

				C. S. Kretschmar, M. Kletzel, K. Murray, P. Thorner, V. Joshi, R. Marcus, E. I. Smith, W. B. London, and R. Castleberry Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study J. Clin. Oncol., October 15, 2004; 22(20): 4119 - 4126. [Abstract] [Full Text] [PDF]

				H. M. Katzenstein, S. L. Cohn, R. M. Shore, D. M.E. Bardo, P. R. Haut, M. Olszewski, J. Schmoldt, D. Liu, A. W. Rademaker, and M. Kletzel Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma J. Clin. Oncol., October 1, 2004; 22(19): 3909 - 3915. [Abstract] [Full Text] [PDF]

				B. H. Kushner Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188. [Abstract] [Full Text] [PDF]

				D. O. Walterhouse, E. R. Lyden, P. P. Breitfeld, S. J. Qualman, M. D. Wharam, and W. H. Meyer Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study J. Clin. Oncol., April 15, 2004; 22(8): 1398 - 1403. [Abstract] [Full Text] [PDF]

				M. A. Smith and B. D. Anderson A Window on Reality? J. Clin. Oncol., April 15, 2004; 22(8): 1360 - 1362. [Full Text] [PDF]

				D. Oosterhoff, M. A. Witlox, V. W. van Beusechem, H. J. Haisma, G. R. Schaap, J. Bras, F. A. Kruyt, B. Molenaar, E. Boven, P. I. J. M. Wuisman, et al. Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 in Vitro and in Vivo by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2 Mol. Cancer Ther., August 1, 2003; 2(8): 765 - 771. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]